which included 407 adults with obesity and moderate knee osteoarthritis. Patients had an average baseline weight of 239.5 pounds and were either given a 2.4-mg weekly dose of semaglutide in the form ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a ...